Friday, December 19, 2025 12/19/2025

Infant blood epigenome and risks of IgE sensitization, obesity, and asthma: MARC-35/43 cohorts

Award Number: R01AI148338
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/13/2020
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

Infant blood epigenome and risks of IgE sensitization, obesity, and asthma: MARC-35/43 cohorts - PROJECT SUMMARY The major challenges for developing primary prevention strategies for childhood asthma are the early identification of modifiable risk factors (e.g., epigenome, IgE sensitization, overweight/ obesity) and the heterogeneity of asthma. The overarching objective of this R01 project is to investigate the role of blood DNA methylation (DNAm) during infancy in the development of three outcomes: IgE sensitization, overweight/obesity (and adiposopathy), and eventually asthma in two complementary multicenter prospective cohort studies. The 35th Multicenter Airway Research Collaboration (MARC-35) study (U01AI087881) is an ongoing 17-center cohort study of 921 infants hospitalized for bronchiolitis – a population at high risk for asthma. Another ongoing cohort study, MARC-43 (UG3/UH3 OD023253), includes 600 healthy infants. These racially/ethnically-diverse cohorts (52% African American or Hispanic) are truly complementary, with participants undergoing similar procedures (e.g., specific IgE and cytokine measurements) at similar ages (e.g., infancy, ages 3 and 6 years). Follow-up includes biannual interviews and medical records to age 6+ years, with ~90% follow-up to date. Participants are undergoing in-person examination at age 6 years for asthma phenotyping. The present R01 project would extend these large well-characterized cohorts by profiling the blood genome-wide DNAm in 1,521 infants, and then examining their relations to the development of the three main outcomes: IgE sensitization, overweight/obesity, and asthma. In Aim 1, we will identify the associations of infant blood DNAm signature with the risk of developing asthma, including its phenotypes. We will also investigate the longitudinal changes of these DNAm from infancy to age 3 years, and their relations to asthma risk. In Aim 2, we will examine the relations of infant blood DNAm signature with the risk of developing IgE sensitization and of overweight/obesity (and adiposopathy). In Aim 3, we will determine the role of IgE sensitization and of overweight/ obesity in the link between infant DNAm and asthma. Our pilot data lend compelling support to these hypotheses. In Aim 4, we will also integrate the available multi-omics data to further define the mechanisms that underlie DNAm signatures identified in Aims 1-3. We will replicate our findings in 963 children from a harmonized birth cohort – the Boston Birth Cohort. The R01 project will provide a unique opportunity to define the mechanisms linking IgE sensitization and overweight/obesity to incident asthma through investigating DNAm during infancy – a critical period of immune and lung development. The project will also provide a strong evidence base for developing targeted interventions for the primary prevention of childhood asthma.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2023	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	1033 MASSACHUSETTS AVE STE 3	CAMBRIDGE	MA	02138	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	4	12/9/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	4	10/30/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $629,086 )
2023	2023	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	4	7/28/2023	NON-COMPETING CONTINUATION	$629,086
														Subtotal = $629,086

Issue Date FY: 2022 ( Subtotal = $629,085 )
2022	2022	HARVARD COLLEGE PRESIDENT & FELLOWS OF	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	3	8/16/2022	NON-COMPETING CONTINUATION	$629,085
														Subtotal = $629,085

Issue Date FY: 2021 ( Subtotal = $629,086 )
2021	2021	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	2	7/14/2021	NON-COMPETING CONTINUATION	$629,086
														Subtotal = $629,086

Issue Date FY: 2020 ( Subtotal = $629,086 )
2020	2020	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	677 HUNTINGTON AVE	BOSTON	MA	02115	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	8/13/2020	NEW	$629,086
														Subtotal = $629,086

Grand Total All Awards = $2,516,343

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Infant blood epigenome and risks of IgE sensitization, obesity, and asthma: MARC-35/43 cohorts

Award Number: R01AI148338

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/13/2020

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer